Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy

Journal of Diabetes and Its Complications
Christof KazdaMarkolf Hanefeld

Abstract

To compare the effects of prandial insulin therapy focusing on postprandial glucose control vs. basal insulin therapy focusing on fasting glucose control in patients with type 2 diabetes. This was an open-label, randomized, parallel, three-arm multicenter trial in patients with type 2 diabetes starting insulin treatment. Patients (n=159) were randomly assigned to 24-week treatment with 3x daily insulin lispro, 3x daily lispro mid mixture (MidMix; 50% lispro, 50% protaminated lispro), or 1x daily insulin glargine; oral antihyperglycemic agents were discontinued. Primary end point was the postprandial glucose excursion 2 h after breakfast at the end of study. Secondary outcomes included HbA1c, self-monitored blood glucose profiles, hypoglycemic episodes, body weight, and patient satisfaction. At the end of study, glucose excursions 2 h after breakfast were significantly lower with lispro and MidMix than with glargine (P<.001 for each vs. glargine): lispro, -0.6+/-2.0 mmol/l; MidMix, +0.8+/-2.4 mmol/l; glargine, +2.5+/-2.4 mmol/l. Fasting glucose decreases were significantly greater with glargine (-2.6+/-2.4 mmol/l) than with lispro or MidMix (-0.9+/-2.2 mmol/l; +0.9+/-1.8 mmol/l). Nevertheless, HbA1c decreased by 1.1% (lispro) an...Continue Reading

References

Jul 8, 1998·Diabetes Care·R A HegeleB Zinman
May 5, 1999·Diabetic Medicine : a Journal of the British Diabetic Association·M HanefeldC Koehler
Dec 28, 2002·Diabetes·Alexandra E ButlerPeter C Butler
Jun 11, 2003·Archives of Internal Medicine·John E Gerich
Jun 26, 2003·Diabetic Medicine : a Journal of the British Diabetic Association·UNKNOWN HOE 901/2004 Study Investigators Group
Oct 28, 2003·Diabetes Care·Matthew C RiddleUNKNOWN Insulin Glargine 4002 Study Investigators
Dec 11, 2003·Diabetologia·A GastaldelliUNKNOWN San Antonio metabolism study

❮ Previous
Next ❯

Citations

Mar 18, 2011·Metabolic Syndrome and Related Disorders·Katherine EspositoDario Giugliano
Jan 30, 2009·Diabetes, Obesity & Metabolism·Mariëlle J P van Avendonk, Guy E H M Rutten
Sep 10, 2013·Diabetology & Metabolic Syndrome·Marcos Antônio TambasciaCarolina Piras de Oliveira
Apr 4, 2012·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Adrian N C LauCatherine H Y Yu
Jan 5, 2012·Expert Opinion on Biological Therapy·Katherine Esposito, Dario Giugliano
Oct 10, 2012·Expert Opinion on Biological Therapy·Katherine EspositoDario Giugliano
May 24, 2011·Journal of Diabetes and Its Complications·Dario GiuglianoKatherine Esposito
May 27, 2008·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·Antonio CerielloUNKNOWN Guideline Development Group
Aug 8, 2008·Primary Care Diabetes·Robert Ligthelm, Jaime Davidson
Jun 12, 2010·Diabetic Medicine : a Journal of the British Diabetic Association·S SarwatR J Heine
Oct 17, 2013·Journal of Diabetes·Svetlana ElizarovaBruce H R Wolffenbuttel
Oct 7, 2010·Journal of Diabetes·David ShromZachary T Bloomgarden
Sep 9, 2010·Diabetes Research and Clinical Practice·Dario GiuglianoKatherine Esposito
Sep 2, 2011·Journal of Diabetes Science and Technology·David Kerr, Tolulope Olateju
Nov 9, 2017·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Gary DeedTed Wu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.